Sensor Life and Overnight Closed Loop: A Randomized Clinical Trial
暂无分享,去创建一个
Malgorzata E. Wilinska | Roman Hovorka | Hood Thabit | Martin Tauschmann | Janet M. Allen | Yue Ruan | Carlo L. Acerini | David B. Dunger | D. Dunger | R. Hovorka | M. Wilinska | C. Acerini | H. Thabit | Y. Ruan | M. Tauschmann
[1] Howard Zisser,et al. Accuracy of the Enlite 6-day glucose sensor with guardian and Veo calibration algorithms. , 2012, Diabetes technology & therapeutics.
[2] Roman Hovorka,et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. , 2016, The New England journal of medicine.
[3] R. Hovorka. Artificial Pancreas Project at Cambridge 2013 , 2015, Diabetic medicine : a journal of the British Diabetic Association.
[4] J. Jansen,et al. Influence of inflammatory cells and serum on the performance of implantable glucose sensors. , 2001, Journal of biomedical materials research.
[5] Claudio Cobelli,et al. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. , 2015, The lancet. Diabetes & endocrinology.
[6] David M Maahs,et al. Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry , 2015, Diabetes Care.
[7] J. Hans DeVries,et al. Accuracy and reliability of continuous glucose monitoring systems: a head-to-head comparison. , 2013, Diabetes technology & therapeutics.
[8] Ahmad Haidar,et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. , 2015, The lancet. Diabetes & endocrinology.
[9] David M Nathan,et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. , 2014, The New England journal of medicine.
[10] J K Mader,et al. Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions , 2014, Diabetes, obesity & metabolism.
[11] Peter Calhoun,et al. Performance comparison of the medtronic sof-sensor and enlite glucose sensors in inpatient studies of individuals with type 1 diabetes. , 2013, Diabetes technology & therapeutics.
[12] Roman Hovorka,et al. Closed-loop insulin delivery: from bench to clinical practice , 2011, Nature Reviews Endocrinology.
[13] G. S. Wilson,et al. Protein interactions with subcutaneously implanted biosensors. , 2006, Biomaterials.
[14] Ben Feldman,et al. Metabolic Biofouling of Glucose Sensors in Vivo: Role of Tissue Microhemorrhages , 2011, Journal of diabetes science and technology.
[15] Ronald Brazg,et al. Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor. , 2014, Diabetes technology & therapeutics.
[16] Lotty Hooft,et al. Continuous glucose monitoring systems for type 1 diabetes mellitus. , 2012, The Cochrane database of systematic reviews.
[17] David Rodbard,et al. Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. , 2016, Diabetes technology & therapeutics.
[18] Malgorzata E. Wilinska,et al. Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial , 2015, Diabetes Care.
[19] B. Wayne Bequette,et al. Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis , 2015, Diabetes Care.
[20] J. Hans DeVries,et al. Continuous Glucose Monitoring, Future Products, and Update on Worldwide Artificial Pancreas Projects. , 2016, Diabetes technology & therapeutics.
[21] E. Atlas,et al. Night glucose control with MD‐Logic artificial pancreas in home setting: a single blind, randomized crossover trial—interim analysis , 2014, Pediatric diabetes.
[22] D. Klonoff,et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. , 2013, The New England journal of medicine.
[23] George Dailey,et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. , 2010, The New England journal of medicine.
[24] Roman Hovorka,et al. Home Use of an Artificial Beta Cell in Type 1 Diabetes. , 2015, The New England journal of medicine.
[25] Janet M. Allen,et al. Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3–6 years: comparison between diluted and standard insulin strength , 2014, BMJ Open Diabetes Research and Care.